ALAMEDA, Calif. & FARMINGTON, Conn.--(BUSINESS WIRE)-- AgeX Therapeutics, Inc.. (AgeX: NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, and Imstem Biotechnology, Inc., a biopharmaceutical company developing human embryonic stem cell-derived mesenchymal stem cells (hES-MSC), today announced their signing of a non-binding letter of intent for ImStem to obtain from AgeX a non-exclusive license to use AgeXs embryonic stem cell line ESI 053 to derive ImStems investigational MSC product IMS001 for development in COVID-19 as well as acute respiratory distress syndrome (ARDS) due to other causes. AgeX and ImStem are co-operating to finalize financial terms and other provisions of a license agreement.
ImStem has previously used AgeX ESI 053 to derive the ImStem IMS001 product which is being investigated for multiple sclerosis under an IND. Earlier this year, the U.S. Food and Drug Administration (FDA) cleared IMS001 to begin a Phase 1 clinical study in patients with multiple sclerosis, after a clinical hold on its Investigational New Drug (IND) application was removed. This is believed to be the first MSC product derived from human embryonic stem cells to be accepted for a clinical trial by the FDA. AgeX and ImStem already have a commercial license in place, which grants ImStem rights to use AgeXs ESI 053 to derive IMS001 as a product candidate for development in autoimmune disease, including multiple sclerosis.
To date, in patients with pneumonia and ARDS due to COVID-19, preliminary literature suggests MSCs, such as ImStems hES-MSC candidate IMS001, may warrant further development consideration. An early clinical study conducted in China by an unrelated group with a different MSC product, Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia, and published in Aging and Disease (2020, Vol. 11, No. 2, pp. 216-228) showed that an intravenous infusion of a different MSC product appeared safe and improved functional outcomes in seven treated patients with COVID-19 pneumonia. MSCs are well recognized to be immunomodulatory in nature, possessing immunosuppressive and anti-inflammatory properties.
Even before their application to COVID-19, MSCs were being investigated as a potential therapeutic option in ARDS, and emerging data in preclinical models has been encouraging. ARDS remains an area of considerable unmet medical need, affecting around 200,000 patients annually in the U.S., accounting for 10% of all intensive care unit patients, and having a mortality of approximately 40%. At the present time, no specific direct therapies exist for ARDS and only supportive treatment is available.
We feel privileged to be part of a global effort to combat COVID-19. This is a unique opportunity for AgeX to leverage its resources to help with the public health challenge at hand. Decades of pioneering work with human embryonic stem cells means this technology is now at a point where it may play a role in the development of a cell-based approach to combating COVID-19. We are very excited by the prospect of expanding our relationship with ImStem to include COVID-19 and ARDS, said Dr. Nafees Malik, Chief Operating Officer of AgeX.
We welcome the opportunity to continue to collaborate with AgeX and explore future development of our IMS001 product in COVID-19 and ARDS from other causes, commented Richard Kim, M.D., Chief Medical Officer of ImStem Biotechnology.
About AgeX Therapeutics
AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics for human aging. AgeXs PureStem and UniverCyte manufacturing and immunotolerance technologies are designed to work together to generate highly defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a variety of diseases with a high unmet medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. AgeXs revolutionary longevity platform induced Tissue Regeneration (iTR) aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues. AGEX-iTR1547 is an iTR-based formulation in preclinical development. HyStem is AgeXs delivery technology to stably engraft PureStem cell therapies in the body. AgeXs core product pipeline is intended to extend human healthspan. AgeX is seeking opportunities to establish licensing and collaboration arrangements around its broad IP estate and proprietary technology platforms and therapy product candidates.
For more information, please visit http://www.agexinc.com or connect with the company on Twitter, LinkedIn, Facebook, and YouTube.
About ImStem Biotechnology
ImStem Biotechnology, Inc. is aspiring to revolutionize how serious diseases with significant unmet needs are treated with a new generation of regenerative and cellular therapies. Pioneering research by its current founder and Chief Technology Officer Dr. Xiaofang Wang and Dr. Ren-He Xu, former director of UConn Stem Cell Institute, led to the proprietary state-of-the-art pluripotent stem cell technology, enabling off-the-shelf, allogeneic stem cell-derived products to be manufactured in scale, differentiating itself from the typical challenges imposed by autologous adult cell therapy products. The company's mission is to advance the science and understanding of human pluripotent stem cell based regenerative cellular therapies through novel and creative development pathways and to fulfill unmet medical needs in serious diseases. And its development strategy focuses on neurologic, autoimmune, degenerative, and rare orphan diseases. ImStem Biotechnology Inc. is a privately held company headquartered in Farmington, CT.
For more information, visit http://www.imstem.com.
Forward-Looking Statements for AgeX
Certain statements contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not historical fact including, but not limited to statements that contain words such as will, believes, plans, anticipates, expects, estimates should also be considered forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of AgeX Therapeutics, Inc. and its subsidiaries, particularly those mentioned in the cautionary statements found in more detail in the Risk Factors section of AgeXs most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commissions (copies of which may be obtained at http://www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. In addition, with respect to AgeXs letter of intent with ImStem there is no assurance that (i) AgeX and ImStem will successfully conclude negotiations and enter into a license agreement; (ii) ImStem will be successful in developing any therapeutic products from a stem cell line licensed by AgeX or that any therapeutic product that may be developed will receive FDA or foreign regulatory approval, or (iii) AgeX will derive revenue or other financial benefits from any license agreement that might be signed with ImStem. AgeX specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200602005353/en/
See the rest here:
AgeX Therapeutics and ImStem Biotechnology Sign Non-Binding Letter of Intent Regarding Investigational MSC Candidate IMS001 for COVID-19 and Other...
- Stem Cell Science and Human Research Studies Ahead of Cargo Arrival - NASA Blogs - February 21st, 2024
- Harvard Stem Cell Institute (HSCI) - December 29th, 2023
- Stem cell - Wikipedia - December 29th, 2023
- A Look Inside Stem Cells Helps Create Personalized Regenerative ... - May 17th, 2023
- Heart disease study shows hope for stem cell treatment - March 4th, 2023
- Focus On Stem Cell Research | National Institute of Neurological ... - March 4th, 2023
- Stem Cell Research: Argumentative Essay - Free Essay Example - Edubirdie - March 4th, 2023
- Automated Cell Culture Systems Market Size to Hit USD 12.43 Billion by 2033; Growing Stem Cell Research & Development and Increasing Prevalence of... - October 21st, 2022
- NIH Guidelines for Human Stem Cell Research - October 13th, 2022
- Ethics of Stem Cell Research - Blue Marble Space Institute of Science - October 13th, 2022
- Global Cell Therapy Market Report (2022 to 2028) - Featuring Thermo Fisher Scientific, MaxCyte, Danaher and Avantor Among Others -... - October 13th, 2022
- Stem Cell Therapy Market (2022-2029) Size Will Escalate Rapidly in the Near Future: Osiris Therapeutics, Molmed - Digital Journal - October 13th, 2022
- Fighting One Disease or Condition per Day - Daily Kos - October 13th, 2022
- The Issue of Tissue: Getting to the Source of the HIV Reservoir - amfAR, The Foundation for AIDS Research - October 13th, 2022
- Cell Isolation Global Market Report 2022: Significant Growth in the Medical and Pharmaceutical Industries Driving Sector - ResearchAndMarkets.com -... - October 13th, 2022
- Nancy and Geoffrey Stack Family Foundation give $2 million to UCI Health - UCI News - October 4th, 2022
- Cell Isolation Market is expected to generate a revenue of USD 20.50 Billion by 2028, Globally, at 15.70% CAGR: Verified Market Research -... - September 25th, 2022
- Creating stem cells from minipigs offers promise for improved treatments - University of Wisconsin-Madison - September 16th, 2022
- Hemostemix Announces the Appointment of Dr. Renzo Cecere, MD, FRCSC to Its Scientific Advisory Board - Yahoo Finance - September 16th, 2022
- Genomics study identifies unique set of proteins that restores hearing in zebrafish - National Institutes of Health (.gov) - September 16th, 2022
- Discovered Key Mechanisms to Improve Intestinal Regeneration and Alleviate the Side Effects of Radiotherapy - Imaging Technology News - September 16th, 2022
- Global Cell Expansion Market Size to Grow at a CAGR of 15% during the Forecast Period 2022-2027 - Digital Journal - September 16th, 2022
- The American Cancer Society Awards $2.1 Million to Montefiore Einstein Cancer Center to Support Cancer Research and Tackle Inequities - Yahoo Finance - September 16th, 2022
- Hair Restoration Market | Stem Cell hair Restoration and Low-level Laser Therapy (LLLT) segment are Expected to Witness Significant CAGR - MDC... - August 30th, 2022
- Stem Cell Therapy for Parkinson's: Current Developments - Healthline - August 5th, 2022
- 'Off the shelf' CAR T cells for cancer treatment? - Boston Children's Answers - Boston Children's Discoveries - August 5th, 2022
- Inflammation accelerates aging of the hematopoietic system - EurekAlert - August 5th, 2022
- New patent-pending method mass-produces antitumor cells to treat blood diseases and cancer - Purdue University - August 5th, 2022
- Cell Therapy Technologies Market worth $8.0 billion by 2027 - Exclusive Report by MarketsandMarkets - PR Newswire - August 5th, 2022
- Twenty-Five Years After My House Call To Dolly: What Have We Learned About Cloning And How Did We Learn It? - Forbes - August 5th, 2022
- Tendon Stem Cell Therapy Market is Booming Worldwide with Strong Growth Prospects | Cellualar Dynamics, Cellectis, International Stem cell... - July 27th, 2022
- [Pangyo Bio & Medical] Theragen Bio discovers MAST4 Protein that Regulates Bone Cartilage Development For 'The First Time in The World' - Digital... - July 27th, 2022
- Cell Culture Media Market Size Worth $10.2 Billion by 2030: Grand View Research, Inc. - PR Newswire - July 27th, 2022
- Cryopreservation Equipment Market Report 2022-2028: Importance of Cryopreservation for Success of Cell-Based Therapies Presents Opportunities -... - July 27th, 2022
- Whitmer axes stem cell research, pregnancy center funding over abortion access concerns - MLive.com - July 19th, 2022
- Stem Cell - National Human Genome Research Institute Home - July 11th, 2022
- Induced Pluripotent Stem Cells (iPS) | UCLA Broad Stem Cell Center - July 11th, 2022
- Global 3D Cell Culture Market To Be Driven By Growing Impact Of Economy On Regenerative Medicine, Emerging Applications Of Gene Therapy During The... - July 11th, 2022
- New Combination Therapy Effective in Pediatric Leukemia - Technology Networks - June 22nd, 2022
- MIT Pioneers Technology To Grow Customizable Wood Products in the Lab With Little Waste - SciTechDaily - June 22nd, 2022
- First-of-its-Kind Stem Cell and Gene Therapy Highlighted at Annual Stem Cell Meeting - Newswise - June 13th, 2022
- Scientists hope this injectable stem cell gel can repair heart attack damage and avoid transplants - Euronews - June 13th, 2022
- Axol Bioscience Introduces CiPA-Validated Human Stem Cell-Derived Ventricular Cardiomyocytes to Help Improve Drug Discovery - Business Wire - June 13th, 2022
- Fasting has pros and cons for muscle repair in mice - Futurity: Research News - June 13th, 2022
- First Clinical Trial of Transplanted 3D Ear Using Human Cells Proves Successful via 3DBio Therapeutics - Tech Times - June 4th, 2022
- Insights on the Dimethyl Sulfoxide (DMSO) Global Market to 2027 - Expanding Research and Development in Stem Cell Transplantation to Benefit Demand... - May 15th, 2022
- Scientists Rejuvenate Skin Cells by 30 Years, with Pioneering Potential - BioSpace - May 15th, 2022
- Global Flow Cytometry Market is expected to grow at a lucrative rate of 8% to reach $11 billion by 2026 A Robust Tool that Defines New Era for... - May 15th, 2022
- Global Mesenchymal Stem Cells Market Research Report to 2027 - Featuring Astellas Pharma, Axol Biosciences and BrainStorm Cell Therapeutics Among... - May 2nd, 2022
- Researchers share insights about the mechanisms of human embryo and create method to develop transcriptionally similar cells in tissue culture -... - May 2nd, 2022
- Flow Cytometry Market is Estimated Drive the Industry Growth Across World in Coming Year 2030 Queen Anne and Mangolia News - Queen Anne and Mangolia... - May 2nd, 2022
- Mini-heart chamber beats on its own just like the real thing - Futurity: Research News - May 2nd, 2022
- The Case Against Embryonic Stem Cell Research: An ... - April 6th, 2022
- Burst of accumulated zinc shows how the mineral boosts immune function, suggesting ways to improve health - EurekAlert - April 6th, 2022
- Hoyer Statement on the Retirement of Congressman Fred Upton - Majority Leader - April 6th, 2022
- 11 Stem Cell Research Pros and Cons Vittana.org - March 25th, 2022
- Research Associate, Cancer and Stem Cell Laboratory job with UNIVERSITY OF SYDNEY | 287031 - Times Higher Education - March 25th, 2022
- Google still has a problem with stem cell and unproven therapies - STAT - STAT - March 25th, 2022
- Medeze Named Frost & Sullivan's 2021 Company of the Year in the Southeast Asia Stem Cell Banking Industry - PR Newswire - March 25th, 2022
- Bone Marrow-Derived Stem Cells (BMSCS) Market Report- Growth in Future with Size, Share, Growth, and Key Companies Analysis Cord Blood Registry... - March 25th, 2022
- Autologous Stem Cell and Non-Stem Cell Based Therapies Market Future Business Opportunities 2022-2028 | Caladrius Biosciences, Vericel Corporation,... - March 25th, 2022
- Cell Therapy Market Trends, Revenue, Key Players, Growth, Share and Forecast Till 2028 Reports and Data - Digital Journal - March 25th, 2022
- This Fancy AF Face Cream Was Invented by a Stem Cell Researcher - VICE - March 25th, 2022
- Freeze Thaw Chambers Market: The cryopreserved products segment is expected to drive the growth of the market - BioSpace - January 5th, 2022
- As Nave as They Get - Weizmann Wonder Wander - News, Features and Discoveries - Weizmann Institute of Science - January 5th, 2022
- Jake's mice: Searching for answers to the puzzle of autism - huntingdondailynews.com - January 5th, 2022
- Primary Cells, Stem Cells, Culture Media and Reagents Market to Witness Rapid Growth by 2029 | BrainStorm Cell Therapeutics Inc., Caladrius... - January 5th, 2022
- Gait Rehabilitation System Market: Rising incidence of various neurological disorders to drive the market - BioSpace - January 5th, 2022
- ARVO Foundation Announces 2022 Bert M. Glaser, MD Award for Innovative Retina Research Recipient - Newswise - January 5th, 2022
- Communication between cells plays a major role in deciding their fate - EurekAlert - December 24th, 2021
- The 10 Most Compelling Research Stories of 2021 - BioSpace - December 24th, 2021
- MRC Lead Apologizes Following Bullying Allegations - The Scientist - December 24th, 2021
- California Proposition 14, Stem Cell Research Institute ... - November 22nd, 2021
- Ethical Issues in Stem Cell Research - PubMed Central (PMC) - November 22nd, 2021
- Opinion | How Covid Raised the Stakes of the War Between Faith and Science - The New York Times - November 8th, 2021
- What is Stem Cell Research? | The Benefits of Stem Cell Research - October 5th, 2021
- An Overview of Stem Cell Research | The Center for Bioethics ... - October 5th, 2021
- Stem Cell Research: Uses, Types & Examples - October 5th, 2021
- Stem Cells | National Institutes of Health (NIH) - October 5th, 2021
- Stem cells: Therapy, controversy, and research - October 5th, 2021